GEO series

p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (PBMC_KB528_timeseries)

GSE274843 Homo sapiens (human) RNA-seq (gene expression) 15 samples Submitted 2025/10/20 Platform GPL34284

At a glance

RNA-seq (gene expression) · human · 15 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Samples: 15 samples
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple MyelomaCancer research · 2026

Summary (written by the submitters)

The oncogenic transcription factor (TF) IRF4 is a universal multiple myeloma (MM) dependency that remains undrugged owing to its disordered structure. Using transcriptional regulatory network (TRN) mapping, an unbiased multi-omic approach to nominate druggable TF cofactors, we identified the chromatin coactivator lysine acetyltransferase (KAT) p300 as a key IRF4 partner.

Read the full summary ↓

We developed KB528, a highly selective p300 KAT inhibitor to explore the regulatory relationship between IRF4 and p300. Instead of broadly inhibiting transcription, partial p300 KAT inhibition selectively downregulates IRF4 and its downstream gene expression program leading to apoptosis selectively in MM cells. IRF4 dependency is a hallmark of MM that exists downstream of existing MM therapies. Consequently, p300 KAT inhibition exhibits strong antiproliferative activity ex vivo and in vivo as a single agent as well as in combination regimens in treatment refractory models. p300 KAT inhibition is well-tolerated in vivo motivating further clinical development in MM.

Published in

Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma

Lenoir WF, McKeown MR, Giorgetti G et al. · Cancer research 2026 · PMID 41248492 · doi:10.1158/0008-5472.CAN-25-3440

This dataset

Open GSE274843 in finder → Find more human RNA-seq datasets →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE274843_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1148169 and SRA study SRP526405. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41248492) ↗

Samples in this study

The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.

+ 15 more — browse all 15 samples with per-sample file links →

Datasets on a similar topic

GSE274845 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (RPMI8226_KB528_timeseries) 15 samples shares kb528, p300, irf4, selectively, inhibition, timeseries, catalytic
GSE274841 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_KB528_timeseries) 15 samples shares kb528, p300, irf4, selectively, inhibition, timeseries, catalytic
GSE274846 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_SOC) 45 samples shares p300, irf4, selectively, inhibition, catalytic
GSE307536 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma 164 samples shares p300, irf4, selectively, inhibition, catalytic
GSE304253 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML. [SLAM-Seq] 35 samples shares p300, inhibition, catalytic
GSE305384 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML 190 samples shares p300, inhibition, catalytic
GSE304612 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML. [ChIP-seq] 95 samples shares p300, inhibition, catalytic
GSE245969 EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells 122 samples shares p300, inhibition

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.